日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011

帕博利珠单抗治疗晚期尿路上皮癌患者(可能不适合接受含铂化疗)的疗效和安全性:KEYNOTE-052 和 LEAP-011 研究的事后分析

O'Donnell, Peter H; Loriot, Yohann; Csoszi, Tibor; Matsubara, Nobuaki; Shin, Sang Joon; Park, Se Hoon; Atduev, Vagif; Gumus, Mahmut; Karaca, Saziye Burcak; Grivas, Petros; de Wit, Ronald; Castellano, Daniel E; Powles, Thomas; Vuky, Jacqueline; Zhao, Yujie; O'Hara, Karen; Okpara, Chinyere E; Franco, Sonia; Homet Moreno, Blanca; Żołnierek, Jakub; Siefker-Radtke, Arlene O

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

一项针对实体瘤患者的 retifanlimab(一种人源化抗 PD-1 单克隆抗体)的 II 期研究 (POD1UM-203)

Di Giacomo, A M; Schenker, M; Medioni, J; Mandziuk, S; Majem, M; Gravis, G; Cornfeld, M; Ranganathan, S; Lou, S; Csoszi, T

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study

按地区分析接受卡博替尼或依维莫司治疗的晚期肾细胞癌患者的预后:METEOR 研究的亚组分析

Schmidinger, Manuela; Motzer, Robert J; Rolland, Frederic; Staehler, Michael; Rink, Michael; Retz, Margitta; Csoszi, Tibor; McCaffrey, John A; De Giorgi, Ugo; Caserta, Claudia; Duran, Ignacio; Benzaghou, Fawzi; Clary, Douglas O; Albiges, Laurence; Choueiri, Toni K; Tannir, Nizar M

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

在接受一线化疗的小细胞肺癌患者中,使用 CDK4/6 抑制剂 trilaciclib 进行骨髓保护:一项 Ib 期/随机 II 期试验

Weiss, J M; Csoszi, T; Maglakelidze, M; Hoyer, R J; Beck, J T; Domine Gomez, M; Lowczak, A; Aljumaily, R; Rocha Lima, C M; Boccia, R V; Hanna, W; Nikolinakos, P; Chiu, V K; Owonikoko, T K; Schuster, S R; Hussein, M A; Richards, D A; Sawrycki, P; Bulat, I; Hamm, J T; Hart, L L; Adler, S; Antal, J M; Lai, A Y; Sorrentino, J A; Yang, Z; Malik, R K; Morris, S R; Roberts, P J; Dragnev, K H

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC

前瞻性观察队列研究,旨在描述帕尼单抗联合化疗在真实世界临床实践中治疗RAS野生型转移性结直肠癌患者的应用情况。

Hebart, Holger; Kiehl, Michael; Tomasek, Jiri; Csoszi, Tibor; Koukakis, Reija; Kafatos, George; Kuhn, Anja; Bjorklof, Katja; Demonty, Gaston; Buchler, Tomas

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Duligotuzumab (MEHD7945A) 与 Cetuximab 治疗头颈部鳞状细胞癌的随机 II 期研究 (MEHGAN 研究)

Fayette, Jérôme; Wirth, Lori; Oprean, Cristina; Udrea, Anghel; Jimeno, Antonio; Rischin, Danny; Nutting, Christopher; Harari, Paul M; Csoszi, Tibor; Cernea, Dana; O'Brien, Paul; Hanley, William D; Kapp, Amy V; Anderson, Maria; Penuel, Elicia; McCall, Bruce; Pirzkall, Andrea; Vermorken, Jan B

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

BOLERO-2 研究揭示了绝经后激素受体阳性晚期乳腺癌患者依维莫司相关不良事件的发生率和时间进程:

Rugo, H S; Pritchard, K I; Gnant, M; Noguchi, S; Piccart, M; Hortobagyi, G; Baselga, J; Perez, A; Geberth, M; Csoszi, T; Chouinard, E; Srimuninnimit, V; Puttawibul, P; Eakle, J; Feng, W; Bauly, H; El-Hashimy, M; Taran, T; Burris, H A 3rd